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ABSTRACT
Background Next generation sequencing has become
the core technology for gene discovery in rare inherited
disorders. However, the interpretation of the numerous
sequence variants identified remains challenging. We
assessed the application of exome sequencing for
diagnostics in complex I deficiency, a disease with vast
genetic heterogeneity.
Methods Ten unrelated individuals with complex
I deficiency were selected for exome sequencing and
sequential bioinformatic filtering. Cellular rescue
experiments were performed to verify pathogenicity of
novel disease alleles.
Results The first filter criterion was ‘Presence of known
pathogenic complex I deficiency variants’. This revealed
homozygous mutations in NDUFS3 and ACAD9 in two
individuals. A second criterion was ‘Presence of two
novel potentially pathogenic variants in a structural gene
of complex I’, which discovered rare variants in NDUFS8
in two unrelated individuals and in NDUFB3 in a third.
Expression of wild-type cDNA in mutant cell lines
rescued complex I activity and assembly, thus providing
a functional validation of their pathogenicity. Using the
third criterion ‘Presence of two potentially pathogenic
variants in a gene encoding a mitochondrial protein’,
loss-of-function mutations in MTFMT were discovered in
two patients. In three patients the molecular genetic
correlate remained unclear and follow-up analysis is
ongoing.
Conclusion Appropriate in silico filtering of exome
sequencing data, coupled with functional validation of
new disease alleles, is effective in rapidly identifying
disease-causative variants in known and new complex
I associated disease genes.
INTRODUCTION
The advent of next generation sequencing
(NGS) technology facilitates the discovery of new
disease genes and is expected to transform and
complement routine clinical diagnosis. This is
particularly true for conditions characterised by
extensive genetic heterogeneity that hampers the
prioritisation of obvious candidate genes and the
identification of causative mutations.
Human mitochondrial respiratory chain complex
I deficiency (MIM 252010) is the most common
biochemical signature of mitochondrial disorders,
a group of highly heterogeneous conditions char-
acterised by faulty oxidative phosphorylation
(OXPHOS), which collectively affects 1 in
5e10 000 live births.1 Human complex I is a giant
multiheteromeric structure of 45 subunits. Among
these are eight Fe-S clusters and an FMN moiety,
which transfer electrons from NADH to ubiqui-
none, using the free energy of this process to pump
protons across the inner mitochondrial membrane.
Seven subunits of complex I are encoded by
mtDNA genes, the remaining ones by nuclear
genes. Several additional gene products have been
shown to contribute to its formation and activity,
and further ones are hypothesised.2 This structural
and functional complexity can explain, at least in
part, the extraordinary heterogeneity of complex
I defects that may range from mild to severe.
Complex I deficiency is known to be associated
with a broad spectrum of clinical presentations,
affecting single or multiple organs at any time in
life.3 Obvious genotype‒phenotype correlations are
missing, making inference from the biochemical or
clinical presentation on the gene involved difficult
or impossible.4 Complex I deficiency is caused by
a large set of disease genes, most of which are still
unknown. In fact, mutations associated with
complex I deficiency have been reported in 21
complex I subunits encoded by the seven mtDNA
genes, and by 17 nuclear genes and in 10 accessory
factors essential for complex I assembly and
stability. However, these genes account for only
half of the biochemically defined cases of complex
I deficiency.5 6 Taken together, these considerations
make complex I deficiency a paradigmatic disorder
to validate NGS protocols for diagnostic purposes.
A major hurdle for NGS to become the standard
approach in routine molecular screening is the
difficulty to distinguish between causal mutations
and thousands of DNA sequence variants present in
each individual. In this context, a distinct advan-
tage of the biochemically well defined OXPHOS
disorders is the possibility to validate the pathoge-
nicity of a given variant by integrating in silico
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analysis with functional complementation in mutant cells
(figure 1).
PATIENTS, MATERIALS AND METHODS
Patients
Informed written consent was obtained from all participants or
their guardians, and the ethics committee of the Technical
University of Munich approved the study. We evaluated 10
index patients with isolated complex I deficiency. This diagnosis
was based on established diagnostic criteria7 and disease mani-
festation was before the age of 3 years. Accordingly, seven
patients (33027, 37796, 44409, 46072, 50845, 59029, 61606) had
residual complex I activities of <25% of the mean of $10
healthy controls. Another three patients (33281, 33284, 33463)
had residual complex I activities between 26% and 40% in
muscle and fibroblasts. Complex II, III, and IV deficiencies were
biochemically excluded in all patients and none of the patients
had a molecular diagnosis before. Rare mtDNA variants had
been excluded by Sanger sequencing of the entire mtDNA. The
clinical presentation and biochemical findings of all patients and
affected siblings are summarised in table 1. A detailed case report
of patient 50845 with causative mutations identified in NDUFB3
is provided in the supplementary data.
Exome sequencing and variant filtering
Within the framework of the German network for rare diseases
‘mitoNET’ and the European E-Rare program ‘GENOMIT’ we
established an exome sequencing and variant filtering pipeline
for the molecular diagnosis of mitochondrial disorders. The
exome of individual 33284 was sequenced as 54 bp paired-end
runs using two lanes of a flowcell on a Genome Analyser IIx
system (Illumina, San Diego, CA, USA) after in-solution
enrichment of exonic sequences using the SureSelect Human All
Exon 38 Mb kit (Agilent, Santa Clara, CA, USA). All other
samples were processed with the SureSelect Human All Exon
50 Mb kit (Agilent) and subsequently sequenced as 76 bp paired-
end runs to an average 120 3 coverage corresponding to
9e12 Gb of sequence data. Read alignment was performed with
BWA (version 0.5.8 or 0.5.9) to the human genome assembly
hg19. Single nucleotide variants and small insertions and dele-
tions were detected with SAMtools (V.0.1.7). Since mitochon-
drial disorders are rare conditions, we excluded variants present
with a frequency >0.4% in 879 control exomes. Assuming an
autosomal recessive mode of inheritance, homozygous or
compound heterozygous variants were searched for (table 2),
yielding a median of 28 mutated genes per individual.
We then applied three sequential filters to identify the causal
mutations: (1) a first filter for disease variants known to be
associated with respiratory chain defects according to the
Human Gene Mutation Database; (2) a second filter based on
the identification of novel homozygous or compound hetero-
zygous variants affecting genes encoding complex I subunits or
known complex I assembly factors; and (3) a third filter for
genes encoding known and predicted mitochondrial proteins
listed in MitoP2.8
Rescue experiments and investigation of complex I assembly
In order to prove the pathogenicity of newly identified missense
alleles, we tested the biochemical rescue of complex I defective
skin fibroblast cell lines from three index cases after lentiviral
mediated expression of wild type (wt) cDNAs using the
p.Lenti6.3/V5-TOPO vector system (Invitrogen).9 Complex I
activity was measured as rotenone-sensitive oxygen consump-
tion rate using the Seahorse system (Bioscience, North Billerica,
MA, USA).10
In the same samples, we also analysed the amount of fully
assembled complex I by immuno-detection on electroblotted
blue-native polyacrylamide gels using an NDUFA9 antibody as
described by Nijtmans et al.11
In patient 50845 carrying the NDUFB3 mutations, we addi-
tionally performed electrophoresis and in-gel quantification of
fluorescent labelled proteins. Standard protocols for solubilisa-
tion and isolation of mitochondrial complexes12 13 were modi-
fied to improve quantification of mitochondrial complexes from
human fibroblasts.14 Briefly, native proteins and protein
complexes in homogenates from 10 mg fibroblasts (wet weight)
were labelled with NHS-fluorescein (Thermo). Sediments
containing mitochondrial membranes were resuspended in
a buffer containing 50 mM NaCl, 50 mM imidazole, 2 mM
aminohexanoic acid, and 1 mM EDTA, pH 7 and solubilised
with 5 ml digitonin (20%). Following 1-D BNE (blue native
electrophoresis) and 2D SDS-PAGE, the 2D gels were scanned
using the blue laser (488 nm) of a Typhoon 9400 scanner (GE
Healthcare) to detect fluorescein labelled proteins in mitochon-
drial complexes. 2D gels were further stained with silver.15 We
used the DIA module (differential in-gel analysis) of the
DeCyder 2D 7.0 software (GE Healthcare) for densitometric
quantification of the fluorescence intensities in 2D gels. A few
clearly visible signals of subunits from ATP synthase, complexes
III and IV, the supercomplexes containing complex I, III, IV, and
the porin complexes16 were selected for quantification (circled).
RESULTS
Exome analysis
By combining unbiased exome analysis, sequential filtering, and
functional investigation, we report here the identification of
disease mutations in five genes in seven out of 10 index cases
with isolated complex I deficiency. The first filter for known
Figure 1 Schematic overview of the exome study in complex I
deficiency. CI, complex I; NSV, non-synonymous variants. Mito-genes
refers to genes coding for known and predicted (MitoP2 SVM score
$1.0) mitochondrial proteins. Numbers in parentheses indicate
estimated numbers for each category.
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complex I deficiency disease alleles identified homozygous
mutations in two individuals, 33463 and 59029. We found
previously reported missense mutations in NDUFS317 (MIM
603864) and ACAD914 (MIM 611126), coding for a structural
complex I subunit and a complex I assembly factor, respectively
(table 3).
The second filter prioritised novel homozygous or compound
heterozygous variants affecting genes encoding complex
I subunits or known complex I assembly factors. Novel variants
in such genes were identified in exomes from individuals 33284
(c.229C>T, p.Arg77Trp; c.476C>A, p.Ala159Asp in NDUFS8
(MIM 602141)), and 50845 (c.64T>C, p.Trp22Arg; c.208G>T,
p.Gly70X in NDUFB3 (MIM 603839)) (table 3). Mutations in
both genes have been previously shown to cause complex
I deficiency.19e21 In individual 33027 we identified variants in
two genes encoding complex I subunits, NDUFS7 (c.124C>T,
p.Pro42Ser; c.514C>A, p.Arg172Ser (MIM 161825)) and NDUFS8
(homozygous c.187G>C/ p.Glu63Gln). Since the equally affected
sister (44559) only carried the homozygous NDUFS8 mutation,
we concluded that the NDUFS7 variants were not responsible
for complex I deficiency.
DNA of available relatives was then tested. Concordant with
a postulated pathogenic role of the NDUFS8 and NDUFB3
variants, affected individuals were homozygous (MITO021) or
compound heterozygous mutants (MITO004, MITO005)
(table 3), while the parents were heterozygous carriers.
Table 1 Clinical and biochemical features of index patients and affected siblings
Pedigree Patient ID number Affected gene Clinical diagnosis
CI/CS
Other featuresMuscle Fibroblasts
MITO005 50845 NDUFB3 comp het ME, MM ND 21%*/17% Muscular hypotonia, developmental delay,
lactic acidosis blood
MITO036 33463 NDUFS3 hom ME, MM 28% 36% Developmental delay, muscular hypotonia,
lactic acidosis, rapid progress of disease
MITO004 33284 NDUFS8 comp het ME, HCM 38% 52% Muscular hypotonia, respiratory
insufficiency
MITO021 33027 NDUFS8 hom LS 8% 54% Muscular hypotonia, dyskinesia, epilepsy,
lactic acidosis, MRI changes
MITO021 44559 NDUFS8 hom LS ND ND Muscular hypotonia, lactic acidosis blood
and CSF, MRI lesions basal ganglia and
brainstem, hypertrophic cardiomyopathy
MITO053 59029 ACAD9 hom HCM 3% ND Muscular hypotonia, lactic acidosis,
exercise intolerance
MITO053 59033 ACAD9 hom HCM ND ND Muscular hypotonia, lactic acidosis,
exercise intolerance
MITO053 59036 ACAD9 hom HCM ND ND Muscular hypotonia, lactic acidosis,
exercise intolerance
MITO049 44409 MTFMT comp het LS 16% ND Vertical gaze palsy, partial optic atrophy,
mental retardation, tetra-spastic,
neurosensoric bladder dysfunction
MITO061 61606 MTFMT hom. LS 12% ND Developmental delay, muscular hypotonia,
ataxia, MRI lesions basal ganglia,
periventricular white matter, dorsal
column
MITO028 33281 Unclear ME 33% 49% Developmental delay, muscular hypotonia,
spastic tetraparesis, brain atrophy and
demyelinisation,
MITO028 37800 Unclear ME ND ND Developmental delay, muscular hypotonia,
spastic tetraparesis, seizures, brain
atrophy, lactic acidosis
MITO038 46072 Unclear ME, MM 4% 27%* Lactic acidosis, developmental delay,
muscular hypotonia, ataxia, coarctation of
aorta
MITO023 37796 Unclear ME 19% 67% Developmental delay, failure to thrive,
muscular hypotonia, seizures, lactic
acidosis
*Normalised to complex IV.
CI/CS, complex I activity normalised to citrate synthase in per cent of mean of >10 controls; comp het, compound heterozygous; CSF, cerebrospinal fluid; hom, homozygous; HCM,
hypertrophic cardiomyopathy; LS, Leigh syndrome; ME, mitochondrial encephalopathy; MM, mitochondrial myopathy; ND, not determined.
Table 2 Variants identified in 10 individuals with complex I deficiency by exome sequencing
Patient ID number 33027 33281 33284 33463 37796 44409 46072 50845 59029 61606
NSV (frequency <0.4% in controls) 2523 450 231 393 261 349 299 246 527 323
Genes with $2 NSV 588 54 13 49 7 23 13 9 36 19
Known disease alleles 0 0 0 1 (NDUFS3) 0 0 0 0 1 (ACAD9) 0
Known complex I subunits and
assembly factors
2 (NDUFS7/8) 0 1 (NDUFS8) 1 0 0 0 1 (NDUFB3) 1 0
Mitochondrial localisation 14 5 1 3 0 1 (MTFMT) 0 1 3 1 (MTFMT)
Mitochondrial localisation refers to genes coding for known mitochondrial proteins and proteins with a MitoP2-score $1.0.
Bold indicates gene carrying the causal mutations.
NSV, missense, nonsense, stoploss, splice site disruption, insertions, deletions.
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In the remaining samples we applied a third filter for genes
encoding mitochondrial proteins listed in MitoP2 (n¼1239).8
This filter revealed that individual 44409 was compound
heterozygous for a maternal mutation c.626C>T, p.Ser209Leu
and a paternal mutation c.994C>T, p.Arg332X in MTFMT
(MIM 611766), the gene encoding mitochondrial methionyl-
tRNA-formyltransferase. MTFMT has so far not been associated
with isolated complex I deficiency. However, the c.626C>T
mutation was recently reported in a family with Leigh
syndrome, impaired mitochondrial translation, and combined
OXPHOS defects.18 The c.626C>T, p.Ser209Leu mutation was
also identified in the homozygous state in patient 52075, with
both reportedly non-consanguineous parents being heterozy-
gous carriers. In addition to the predicted p.Ser209Leu change,
c.626C>T has been demonstrated to cause skipping of exon 4
resulting in a frameshift and premature stop codon,
p.Arg181SerfsX5.18 The second mutation found in individual
44409, c.994C>T, p.Arg332X, determines the synthesis of
a truncated variant missing the highly conserved C-terminal
portion of the protein. Thus, both mutations are shown or
predicted to severely impair the function of MTFMT, supporting
their pathogenic impact. In metazoan mitochondria, tRNAMET
plays a role in both translationinitiation as well as translation
elongation. MTFMT formylates Met-tRNAMet to form fMet-
tRNAMet. Formylated methionine-tRNA has high affinity to,
and is preferentially recruited by, mitochondrial translation
initiation factor (IF2mt) to theribosomal P site for translation
initiation.22
Confirmation of the pathogenicity of NDUFS8 and NDUFB3
mutations
The newly identified disease segregating missense mutations in
NDUFS8 and NDUFB3 affected amino acid residues conserved in
>85% of at least 39 vertebrates. Nevertheless, their pathogenic
role remained to be proven. To this aim, complementation
experiments were performed followed by functional and protein
level investigations. Expression of NDUFS8wt cDNA in fibro-
blasts of individuals 33284 and 33027, and NDUFB3wt in cells of
patient 50845, led to a significant increase of complex I activity
(figure 2). In the same samples, we also analysed the amount of
fully assembled complex I by blue-native PAGE electrophoresis.
The complex I content was consistently low in naïve cells, but
increased significantly after expression of the corresponding wild
type cDNA (figure 2).
Since expression of the NDUFB3wt cDNA re-established
complex I dependent respiration to low normal levels, we
further tested the functional consequence of the identified
variants in NDUFB3. The low complex I activity found in naïve
cells of patient 50845 (17% of controls) remained unchanged
after expression of NDUFB3 cDNA carrying either the
p.Trp22Arg or the p.Gly70X mutations (figure 3). In parallel we
Table 3 New genetic diagnoses for seven index cases with complex I deficiency
Pedigree Patient ID number Gene Position (hg19) dbSNP Transcript
Variations
Supporting evidenceNucleotide Amino acid






Rescue, seg, conserv, truncation
MITO036 33463 NDUFS3 chr11:47603988 rs104894270 NM_004551.2 c.532C>T hom p.Arg199Trp Known disease variant17







MITO021 33027 NDUFS8 chr11:67800467 NM_002496.3 c.187G>C hom* p.Glu63Gln Rescue, seg, conserv
MITO053 59029 ACAD9 chr3:128528894 NM_014049.4 c.1594C>T hom p.Arg532Trp Known disease variant14







Truncation, seg, known disease variant,18
skipping exon 4
MITO061 61606 MTFMT chr15:65313871 NM_139242.3 c.626C>T hom p.Arg181SerfsX5
(p.Ser209Leu)
Known disease variant,18 skipping exon 4
*Previously undescribed DNA variant.
conserv, amino acid conserved in $85% of 39e42 vertebrate species; het, heterozygous; hom, homozygous; rescue, pathogenicity established by rescue of complex I defect in patient
fibroblasts; seg, variant segregates with disease phenotype in family.
Figure 2 Introduction of NDUFS8 and NDUFB3 cDNA rescues both
amount and activity of complex I in subject fibroblasts. The mutations in
NDUFS8 and NDUFB3 result in decreased activity and amount of
complex I. (A) 30 mg digitonin-solubilised protein from control and
patients 33027, 33284, 50845 fibroblasts were separated on a 4e16%
acrylamide blue-native PAGE (Novex System, Invitrogen), transferred on
PVDF membrane and immuno-decorated with antibodies specific for
subunits NDUFA9 of complex I and core II of complex III (1:1000;
MitoSciences, Eugene, Oregon, USA). The analysis shows reduced
amounts of subunit NDUFA9 assembled in supercomplex 0 and 1 (S0,
S1) in patient cell lines indicating a decreased amount of whole complex
I. (B) Control and patient fibroblasts were seeded at 20 000 cells/well in
80 ml DMEM, and incubated at 378C, 5% CO2 for 24 h. Oxygen
consumption rates (OCR) were measured using the XF96 extracellular
flux analyser (Seahorse bioscience). The OCR was determined with no
additions, and after addition of oligomycin (1 mM), carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone (FCCP, 0,4 mM), and rotenone
(5 mM). Complex I activity was calculated as rotenone-sensitive OCR.
Both amount and activity of complex I are rescued upon lentiviral-
mediated stable expression of NDUFS8wt and NDUFB3wt cDNA. Data
shown are mean of >10 biological replicates 6 SD. ***p<0.001.
280 J Med Genet 2012;49:277e283. doi:10.1136/jmedgenet-2012-100846
Diagnostics
group.bmj.com on November 20, 2014 - Published by http://jmg.bmj.com/Downloaded from 
also showed that the NDUFB3 protein was absent in naïve cells
of patient 50845, but present in an amount comparable to
controls after transduction with the NDUFB3wt cDNA. The
same effect was also observed for the NDUFB8 and NDUFS3
subunits, indicating a general assembly/stability defect of
complex I. The impaired complex I assembly or stability due to
NDUFB3 mutations was further confirmed by two-dimensional
blue-native/SDS-PAGE separation and quantification of fluores-
cein-labelled mitochondrial complexes (figure 4). Comparing
patient and control fibroblast, the signal intensity of complex III
was of the same level. Complex IV and V of patient fibroblasts
were reduced to 48% and 76%, respectively. The supercomplexes
were not detectable in the patient. After the transduction of the
patient cell line with the NDUFB3wt, the amounts of mito-
chondrial supercomplexes in patient fibroblasts increased up to
43% of the control. The amounts of complexes III, IV, and V did
not change significantly.
Taken together, these results demonstrate the causal role of
the mutations identified in NDUFS8 and NDUFB3, thereby
establishing NDUFB3 as a gene responsible for human complex
I deficiency.
DISCUSSION
In this study, increasingly wider variant filters were applied on
exome sequencing datasets, in combination with functional
complementation, to identify causative mutations in single
individuals with complex I deficiency. Filtering of rare variants
was facilitated by the availability of a large set of control exomes
(n¼879), and pathogenic mutations were identified using
mutation databases and in silico selection of genes encoding
known or potential mitochondrial proteins. Importantly, when
the list of genes was further processed against public data-
basesdfor example, exclusion of variants present in dbSNP with
an average heterozygosity of more than 0.02dthe number of
candidate genes was reduced by just one or two entries. The
only exception was a sub-Saharian African individual (33027),
whose gene variation dataset matched poorly with our set that
was largely composed of Europeans.
Our stepwise filtering approach successfully identified vari-
ants in NDUFB3. Complementation experiments established the
pathogenicity of the mutations. Two previous large candidate-
gene based screening studies failed to identify rare DNA variants
in the NDUFB3 gene among 1035 and 1526 patients with
complex I deficiency. NDUFB3 variants were found only recently
in a screen of 42 patients19 with infantile onset mitochondrial
disorders, suggesting that mutations in NDUFB3 are rare.
Figure 3 Expression of mitochondrial complex I subunits/complex I
assembly. For Western-blot analysis 20 mg of total cell protein from
patient 50845 and control (Ct) skin cultured fibroblasts with ectopic
expression of wild type (wt) form or mutated versions of NDUFB3 cDNA
were separated and immuno-decorated with antibodies specific for
subunits of the respiratory chain complex I (NDUFB3, NDUFB8,
NDUFS3) and subunit core II of complex III as control (MitoSciences
1:1000). Only expression of NDUFB3wt cDNA rescued complex I (A) and
restored normal levels of several other complex I subunits (B). ms,
NDUFB3 cDNA carrying the c.64T>C missense variant; ns, NDUFB3
cDNA with the c.208G>T stop mutation.
Figure 4 Mito-Panorama: two dimensional (2D) BN/SDS-PAGE separation and quantification of fluorescein labelled mitochondrial complexes and
supercomplexes. For analysis we used 10 mg of control fibroblasts (A) and patient 50845 fibroblasts before (B) and after (C) transduction with the
NDUFB3wt construct. 2D gel area for 3D visualisation see supplementary figure 1. Assignment of complexes: S, supercomplexes composed of
respiratory chain complexes I, III, and IV, V, complex V or ATP synthase; III, complex III or cytochrome c reductase; IV, complex IV or cytochrome c
oxidase; Phb1/2, prohibitin complex and P for porin complexes, which were used for normalisation. D, densitometric quantification of mitochondrial
complexes in 2D BN/SDS-PAGE from human fibroblasts, expressed as per cent of healthy control cells (two technical replicates). Arrows indicate
fluorescent signals used for complex quantification that are visible in this 3D view.
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NDUFB3 is a single transmembrane domain subunit localised in
the QD module of the complex I membrane armdbeing one of
the many complex I accessory subunits23 present in eukaryotes
but not in bacterial complex Idwhich play a role in regulation,
assembly and stability of the 14 subunit catalytic core of
complex I, possibly protecting it from reactive oxygen species
damage.24 The ancillary but essential role of the complex I
accessory subunits is confirmed by the identification of muta-
tions resulting in impaired complex I activity in eight of them,
including NDUFB3 (present study).
Filtering for genes encoding mitochondrial proteins revealed
loss-of-function mutations in MTFMT in two patients. The very
same disease allele, c.626C>T, shared by patients 44409 and
61606 has also been reported in a patient presenting with
a biochemical signature of combined respiratory chain defi-
ciency.18 MTFMT is a protein involved in mtDNA translation,
which suggests that complex I deficiency can be a biochemical
signature common to mutations of genes neither directly nor
exclusively involved in complex I formation and activity. Giant
size, structural complexity and intricate functional and struc-
tural interactions with other respiratory chain components and
mitochondrial pathways are likely concurring to make complex
I an exquisitely sensitive target in a wide spectrum of patho-
logical conditions related to OXPHOS. For example, seven of the
13 mtDNA encoded proteins are complex I subunits, which
could explain why mtDNA translation defects such as those
associated with mutations in MTFMTcan predominantly impair
complex I activity (table 4).
These considerations have relevant implications for the diag-
nostic workup and for the elucidation of complex I functions
and interactions.
Three individuals remained genetically undefined even after
exome analysis, which may be due to: (1) insufficient gene
coverage; (2) too stringent filtering; (3) mutations in non-coding
regions or non-annotated exons; (4) heterozygous deletions of
whole exons; or (5) non-autosomal recessive mode of inheri-
tance. However, the third filter detected between 0‒5 mito-
chondrial proteins. We are currently analysing the candidate
genes in the unsolved cases. An interesting finding of our present
study confirming a previous report14 is the identification of
unexpected disease genes associated with complex I patho-
physiology: the first example has been the recently identified
gene encoding ACAD9, a bona fide component of the b oxida-
tion of fatty acids, followed here by MTFMT. Along the same
line, the individuals that escaped the mitochondrial filter are of
special interest, since they offer the possibility to discover
mutations in genes so far unlinked to mitochondrial function.
This option, important for many patients, would have been
missed in an approach focused on genes predicted to code for
mitochondrial proteins only.19
In summary, this study demonstrates the efficacy of exome
sequencing, coupled with prioritisation for mitochondrial
proteins and experimental validation, to elucidate the genetic
basis of a metabolic disorder with extreme locus heterogeneity.
This integrated strategy can be further exploited to define fully
the gene repertoire involved in complex I deficiency and in other
mitochondrial disorders displaying a biochemical phenotype at
the cellular level. In some cases, as for family MITO053 with
mutations in ACAD9, the identification of the disease gene offers
the pathophysiological basis for promising therapeutic inter-
ventionsdfor example, the high dose supplementation with
riboflavin.14 25 26
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Table 4 Biochemical analysis of OXPHOS complexes in muscle biopsy in individuals 44409 and 61606 harbouring MTFMT mutations
OXPHOS complex
Activity in muscle (44409) Activity in muscle (61606)
Patient Reference range Patient Reference range
CI 0.026 0.07e0.25 0.03 0.14e0.35
CII 0.154 0.067e0.177 0.29 0.18e0.41
CIII 2.889 2.50e6.61 1.48 1.45e3.76
CIV 0.929 0.81e3.12 1.30 0.91e2.24
CII+CIII 0.416 0.30e0.97 0.50 0.30e0.67
Activity values of complexes I, II, III, IV (CI-IV) are given relative to citrate synthase (CS) in mUnit/mUnit CS.
Italics and bold indicate abnormal value.
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